Huntington’s Disease: New Pathway for Protein Spread Identified, Potential Drug Target Found

Huntington’s disease, a relentlessly progressive and devastating brain disorder, slowly erodes a person’s ability to move, think, and regulate emotions. A recent breakthrough from Florida Atlantic University (FAU) and collaborating institutions offers a new avenue for slowing the progression of this disease by pinpointing how a toxic protein spreads within the brain. Researchers have identified microscopic channels, termed tunneling nanotubes (TNTs), that act as direct conduits for the transmission of harmful proteins between brain cells.

For years, scientists have understood that the mutant huntingtin protein, the root cause of Huntington’s, doesn’t remain localized; it spreads from neuron to neuron. Though, the precise mechanisms driving this intercellular spread remained elusive – until now. The study, published in Science Advances, demonstrates that disrupting the formation of these TNTs significantly reduces the spread of the disease-causing protein in laboratory models.

How ‘Tunneling Nanotubes’ Facilitate Disease Spread

Unlike traditional cell communication, which relies on chemical signals traveling through the space between cells, TNTs provide a direct, physical connection. These tube-like structures allow cells to “hand-deliver” proteins and other cellular materials directly to their neighbors. While this exchange can be beneficial in certain circumstances, such as during cellular stress responses, in Huntington’s disease, TNTs are exploited as pathways for the toxic mutant huntingtin protein to propagate neurodegeneration. This isn’t simply a matter of proteins leaking; it’s a directed transfer.

The FAU research team discovered that a protein called Rhes plays a crucial role in the formation of these TNTs. Interestingly, Rhes partners with another protein, SLC4A7 – a bicarbonate transporter typically associated with regulating acidity within cells – to build these microscopic tunnels. Together, they create highways that allow the toxic huntingtin protein to move from one neuron to another. This partnership was unexpected, adding a new layer of complexity to understanding the disease process.

Identifying a Potential Drug Target: SLC4A7

“This operate fundamentally changes how we think about disease progression in Huntington’s,” explains Srinivasa Subramaniam, Ph.D., senior author of the study and an associate professor at FAU’s Department of Chemistry and Biochemistry. “We’ve known that neurons somehow pass toxic proteins to one another, but now One can see the machinery that makes that possible. By identifying SLC4A7 as a key partner of Rhes, we’ve uncovered a new and potentially druggable target to stop that spread at its source.”

The researchers demonstrated that when they blocked SLC4A7 – either genetically or using pharmaceutical interventions – the formation of TNTs was inhibited, and the spread of the toxic huntingtin protein was substantially reduced. This effect wasn’t limited to cells grown in a lab; in mouse models of Huntington’s disease, mice lacking SLC4A7 exhibited a dramatic decrease in the transfer of the toxic protein between neurons in the striatum, the brain region most severely affected by the disease. This suggests that targeting this pathway could offer a therapeutic strategy for slowing disease progression.

Beyond Huntington’s: Implications for Other Neurodegenerative Diseases

The implications of this research extend beyond Huntington’s disease. Tunneling nanotubes have been implicated in other neurodegenerative disorders, including those involving the tau protein, a hallmark of Alzheimer’s disease. They also appear to play a role in cancer, where tumor cells utilize similar structures to share signals, energy, and even drug resistance. Because both Rhes and SLC4A7 are involved in fundamental cellular processes, the newly identified pathway may represent a common mechanism underlying the spread of damage in a variety of diseases. Florida Atlantic University’s Brain Institute is actively exploring these broader connections.

Understanding Huntington’s Disease: A Rare and Devastating Condition

Huntington’s disease is a rare, inherited brain disorder affecting approximately three to seven people per 100,000 worldwide. It impacts men and women equally. Symptoms typically emerge between the ages of 30 and 50 and progressively worsen, leading to uncontrolled movements, cognitive decline, and significant psychiatric symptoms. Individuals with a parent affected by Huntington’s disease have a 50 percent chance of inheriting the gene and developing the condition. Currently, there is no cure, and existing treatments only manage symptoms without halting the disease’s progression. Following the onset of symptoms, individuals typically live for another 10 to 20 years, often experiencing increasing disability and loss of independence.

The Future of Huntington’s Disease Research

“This research shines a spotlight on an entirely new way cells communicate in health and disease,” says Randy Blakely, Ph.D., executive director of the FAU Stiles-Nicholson Brain Institute. “By learning how harmful proteins physically move from cell to cell, we gain powerful new leverage points for therapy. The idea that we could slow or even halt disease progression by blocking these microscopic tunnels opens an exciting frontier for treating not only Huntington’s disease, but a wide range of neurological disorders and cancers in the future.”

The next steps involve further investigation into the precise mechanisms regulating TNT formation and function. Researchers are also exploring potential therapeutic strategies to specifically target the Rhes-SLC4A7 interaction, with the goal of developing drugs that can effectively block the spread of toxic proteins without disrupting essential cellular processes. Clinical trials will be necessary to determine the safety and efficacy of any such interventions. The discovery also underscores the importance of continued research into cellular communication pathways and their role in disease pathogenesis. This work is likely to spur further investigation into the role of TNTs in other neurological conditions and cancers, potentially leading to new therapeutic targets and strategies.